genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2021 on Tuesday, 29 March 2022.
The Company will provide a live presentation to accompany the interim results, presented by CEO, David Budd and CFO, Matthew Fowler on Thursday, 31 March 2022 at 10.00 am.
The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet genedrive plc via the following link: https://www.investormeetcompany.com/genedrive-plc/register-investor
For further details please contact:
genedrive plc
+44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO
About genedrive plc ( http://www.genedriveplc.com ) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and a test to help in the prevention of hearing loss caused by certain antibiotics in neonates. The Company recently released point of care test for Covid-19.
